beta cells

ViaCyte on the Rise: First Diabetes Trial Data & Acquires BetaLogics IP

VC-01-post-implant-final1-e1503703572933

Clinical research on Type I Diabetes is one of the most exciting and promising areas of stem cells and regenerative medicine for human disease. Two of the coolest companies out there in this arena have been ViaCyte and BetaLogics (owned by J&J). For more on ViaCyte see my interview with President and CEO Paul Laikind …

ViaCyte on the Rise: First Diabetes Trial Data & Acquires BetaLogics IP Read More »

New biotech Semma Therapeutics stem cell diabetes arena

Semma_05-4065

A new biotech startup, Semma Therapeutics, announced that it seeks to fight diabetes via translating technology from the lab of Doug Melton at Harvard to the clinic. Update: Note that the firm was recently acquired by Vertex. Another major player in cell therapy-based arena for Diabetes is most likely good news for patients. Quoted in the Boston …

New biotech Semma Therapeutics stem cell diabetes arena Read More »

ViaCyte CEO Laikind Interview: Trial Update, Melton, & Future

VC-01-post-implant-final1-e1503703572933

It’s been exciting to watch the recent developments in using stem cells as the basis for treatments for Type I Diabetes. One of the major players in this arena is the privately-held company, ViaCyte. In this post, I interview ViaCyte President and CEO, Paul Laikind. The topics include their VC-01 product, the Encaptra device, an update on …

ViaCyte CEO Laikind Interview: Trial Update, Melton, & Future Read More »